Trial Profile
Phase 1b Double-blind Study to Assess the Safety, Tolerability and Preliminary Efficacy of Intra-articular Administration of Resiniferatoxin Versus Placebo for the Treatment of Pain Due to Moderate to Severe Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Sorrento Therapeutics
- 07 Sep 2023 According to a Sorrento Therapeutics media release, the company has completed the one-year follow up for the last patient dosed in February 2021.
- 22 May 2023 According to a Sorrento Therapeutics media release, resiniferatoxin received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee, based on data from phase I and phase II studies.
- 26 Sep 2022 According to a Sorrento Therapeutics media release, the phase 2 study NCT04885972 was conducted following the analysis of the positive observations from this trial.